Leipzg, Germany Clinical Trials

A listing of Leipzg, Germany clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 14 clinical trials
A Study to Determine the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

The main objective of this study is to assess safety, tolerability, and pharmacokinetics (PK) of ABBV-368 plus tilsotolimod; ABBV-368 plus tilsotolimod and nab-paclitaxel; and ABBV-368 plus tilsotolimod, nab-paclitaxel, and ABBV-181 in participants with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

Universitaetsklinikum Leipzig /ID# 214200
 (0.9 away) Contact site
  • 22 views
  • 27 Jan, 2021
  • +41 other locations
Study of AMG 199 in Subjects With MUC17-Positive Gastric and Gastroesophageal Junction Cancer

To evaluate the safety and tolerability of AMG 199 in adult subjects with MUC17-positive gastric and gastroesophageal junction cancer and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).

Research Site
 (0.9 away) Contact site
  • 7 views
  • 13 Jun, 2021
  • +38 other locations
A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients

The study aims to evaluate the safety and tolerability of subcutaneous (SC) blinatumomab for treatment of Acute Lymphoblastic Leukemia (ALL) and to determine the maximum tolerated dose (MTD), and recommended phase 2 dose (RP2D) of SC administered blinatumomab.

Universitaetsklinikum Leipzig Anstalt des oeffentlichen Rechts
 (0.9 away) Contact site
  • 0 views
  • 11 Jun, 2021
  • +33 other locations
Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

To evaluate the safety and tolerability of AMG 910 in adult subjects, and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D)

Research Site
 (0.9 away) Contact site
  • 0 views
  • 11 Jun, 2021
  • +20 other locations
A Study of JNJ-64619178 an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors NHL and Lower Risk MDS

The purpose of the study is to identify the maximum tolerated dose (MTD) of JNJ-64619178 in participants with relapsed/refractory B cell non-Hodgkin lymphoma (NHL) or advanced solid tumors and also to identify the recommended Phase 2 dose(s) (RP2Ds) of JNJ-64619178 for NHL and advanced solid tumors (Part 1) and to …

human chorionic gonadotropin
hodgkin's disease
solid tumour
solid neoplasm
beta human chorionic gonadotropin
Universitatsklinikum Leipzig
 (0.9 away) Contact site
  • 152 views
  • 31 May, 2021
  • +29 other locations
Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection

This is a Phase 1 study in which healthy volunteers and participants with chronic HBV infection will receive VIR-3434 or placebo and will be assessed for safety, tolerability, pharmacokinetics (PK), and antiviral activity (only in participants with chronic HBV infection).

antiviral drugs
hepatitis
chronic hepatitis
Investigative Site
 (130.5 away) Contact site
  • 117 views
  • 11 May, 2021
  • +18 other locations
A Study Investigate the Safety Tolerability Pharmacokinetic and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome

This study will investigate the safety and tolerability of SLN124 in patients with Thalassaemia or patients with Very Low- and Low-risk Myelodysplastic Syndrome after single ascending s.c. doses and multiple doses in healthy male and female subjects. Up to 7 cohorts of 56 patients with Thalassaemia and up to 7 …

Germany
 (241.1 away) Contact site
  • 0 views
  • 22 Mar, 2021
  • +13 other locations
A Study of H3B-8800 in Participants With Myelodysplastic Syndromes Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia

This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of H3B-8800 in subset of participants with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML). The study consists of two parts, a dose …

myelodysplastic syndromes
decitabine
myelomonocytic leukemia
azacitidine
chronic myelomonocytic leukemia
Eisai Trial Site 2
 (62.1 away) Contact site
  • 0 views
  • 23 Mar, 2021
  • +26 other locations
Study of Intratumoral CV8102 in cMEL cSCC hnSCC and ACC

This study evaluates intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma. Patients will receive CV8102 as single agent or in combination with SoC anti-PD-1 therapy.

squamous cell carcinoma of the head and neck
pembrolizumab
carcinoma
head and neck carcinoma
melanoma skin
Investigative Site
 (44.2 away) Contact site
  • 136 views
  • 29 Jan, 2021
  • +29 other locations
This Study Tests the Safety of Inhaled BAY1237592 How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

In this trial the effects of the inhaled drug BAY1237592 will be studied in patients with high blood pressure affecting the blood vessels in the lungs due to Pulmonary Arterial Hypertension (PAH) and due to Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Pulmonary hypertension is characterized by the elevation of pressure in …

chronic thromboembolic pulmonary hypertension
iloprost
pulmonary arterial hypertension
prostaglandin
nitric oxide
Universit tsklinikum Leipzig A R
 (0.9 away) Contact site
  • 69 views
  • 14 Jun, 2021
  • +57 other locations